AOD-9604: The Fragment That Didn't Beat Placebo

The short version

AOD-9604 is a synthetic 16-amino-acid peptide — a hexadecapeptide — modeled on the tail end of human growth hormone, the part of the hormone thought to control fat breakdown rather than growth. It was designed to keep that one activity while leaving behind the parts of growth hormone that raise blood sugar and drive tissue growth.

In mice, the idea worked: chronic dosing reduced body fat and increased a receptor linked to fat-burning, and blocking that receptor abolished the effect ^[9][10]. In humans, it did not hold up the same way. Across roughly six clinical trials totaling about 900 people with obesity, AOD-9604 was well tolerated — its side-effect profile was indistinguishable from placebo — but the pivotal obesity trial did not show statistically significant weight loss over placebo, and its drug-development program was discontinued ^[8]. AOD-9604 is not FDA-approved for any use and is sold, where it is sold, strictly as a research chemical.

What it is

AOD-9604 is a synthetic 16-amino-acid peptide modeled on residues 177–191 of human growth hormone — the hormone's C-terminal, or tail, region — with one substitution: an added tyrosine in place of the natural amino acid at the very start of the chain. Two cysteines within the sequence form a small internal loop, a disulfide bridge, that mirrors a structural feature of the full-length hormone.

The reported sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. Unlike full-length growth hormone, AOD-9604 does not bind the growth hormone receptor at all — that is the entire premise of the fragment approach: keep the piece of the hormone associated with fat metabolism, discard the piece that binds the receptor responsible for growth-promoting and blood-sugar-raising effects.

How it works

In rodent studies, AOD-9604 reduces body fat through two linked actions: it inhibits an enzyme (acetyl-CoA carboxylase) involved in building new fat from scratch, and it increases the amount of a receptor called the beta-3 adrenergic receptor on fat cells, which promotes burning stored fat for energy. When researchers bred mice that lack a working beta-3 adrenergic receptor, AOD-9604's chronic weight- and fat-reducing effect disappeared entirely, even though a short-term boost in fat oxidation still occurred — evidence that the receptor is required for the durable effect but not for every acute one ^[9].

Because AOD-9604 does not engage the growth hormone receptor, it was expected to avoid the fluid retention, joint discomfort, and blood-sugar effects associated with growth hormone and growth-hormone-releasing compounds — and the human safety data are broadly consistent with that expectation ^[8].

What the research shows

Osteoarthritis model (unrelated to obesity). In a rabbit model of induced knee osteoarthritis, weekly injections of AOD-9604 directly into the joint — with or without hyaluronic acid — reduced measures of cartilage degeneration compared with saline over four to seven weeks. This preclinical, joint-injection use is mechanistically and clinically distinct from the oral anti-obesity use AOD-9604 was originally developed for ^[6].

Non-clinical safety and pharmacokinetics. A non-clinical evaluation in rats and primates found no genotoxic or toxicological concerns and generally favorable safety after chronic oral dosing. Its half-life after intravenous injection was very short — about three minutes — and the peptide is broken down through sequential removal of amino acids from one end of the chain ^[7].

Human safety and tolerability program. Across roughly six clinical trials totaling about 900 obese adults, oral AOD-9604 at doses from 0.25 mg to 54 mg daily, lasting 7 days to 24 weeks, produced a safety and tolerability profile indistinguishable from placebo, without the adverse effects associated with full-length growth hormone ^[8].

Mechanism in obese mice. After 14 days of treatment, both full-length human growth hormone and AOD-9604 reduced body weight and fat in obese mice and increased beta-3 adrenergic receptor expression. In mice genetically engineered to lack that receptor, the chronic weight-loss effect of both compounds disappeared, while an acute, short-term increase in energy expenditure and fat oxidation still occurred ^[9].

Fat oxidation and weight loss in obese mice. A related study found that chronic treatment with either full-length growth hormone or the modified C-terminal fragment increased fat oxidation and produced weight loss in obese mice, in the same direction as intact growth hormone ^[10].

Reported effects, cautions & safety

Reported experience — anecdotal, not clinical evidence. In fat-loss and research-peptide communities, the single most common report about AOD-9604 is that people do not notice meaningful fat loss — a pattern that lines up with the human obesity trials failing to beat placebo. Most describe it as well tolerated with few complaints, without the water retention, joint puffiness, or tingling that people associate with growth hormone or growth-hormone-releasing compounds. A subset mention a mild lift in energy or a modestly reduced appetite, though these reports are impossible to separate from concurrent diet changes, and they were not outcomes the clinical trial program measured. Community claims that injecting near a specific area melts fat there specifically are not supported by any human trial and are biologically implausible — the body does not lose fat by injection site. A recurring theme, including from clinicians who discuss the compound, is that fat-loss-peptide marketing oversells what the human evidence actually shows.

Cited cautions from the clinical literature. AOD-9604 was developed as an anti-obesity drug candidate but never gained marketing approval anywhere; it has no approved indication, dosing, or manufacturing quality standard, so any use outside a trial is experimental and unverified ^[8]. Its pivotal human obesity trial did not demonstrate statistically significant weight loss versus placebo, and the drug-development program was discontinued as a result — expectations of fat loss are not supported by the clinical evidence ^[9]. The fat-metabolism mechanism was worked out chiefly in mouse, rat, and cell studies; that mechanistic promise did not translate into a proven human fat-loss effect, a reminder that animal efficacy does not guarantee human benefit ^[9]. Reported human exposure comes from trials of at most about 24 weeks, so long-term safety beyond that window is uncharacterized.

Where it fits in metabolic signaling

AOD-9604 sits at the tissue-fragment layer of this desk's map — an attempt to extract one useful activity from a much larger, more complicated hormone rather than engaging a receptor system directly, the way semaglutide does, or working from inside the cell, the way MOTS-c does. Its story is also the most sobering one on this desk: mechanistically coherent rodent data that did not survive contact with a well-run human obesity trial. That gap between animal promise and human result is exactly the kind of distinction this desk exists to keep visible rather than blur. See the comparison page for how the three stack up.